After a lot of hard work and excellent continued team work, all objectives of COMBACTE-CARE’s EURECA study were completed, including an over-inclusion of 10% of subjects for each subgroup.
With a total of 2266 patients enrolled, the team is now in the process of site closing, and working with microbiological samples at the central laboratory in Antwerp, Belgium.
With over 17,000 queries solved, 75% of sites have been already closed and 95% of microbiological samples are already at the lab central, with a really high percentage of microbiological confirmation, allowing the certainty that the study objectives will be achieved.
The initial analysis will be initiated in the coming months and the first study results are expected in Q4 2019.
The team really appreciates the huge effort and commitment of all the partners and local investigators in the EURECA study, which made achievement of all recruitment objectives possible. Excellent collaboration between the central team and the study sites has ensured that the study has run smoothly, and in future will lead to results that have a significant impact on the practice of infectious diseases in Europe and elsewhere.
EURECA is a prospective observational study on cohorts of patients with serious carbapenem-resistant Gram-negative bacterial infections. It aims to learn how patients across Europe are infected and currently treated. And which subgroups of patients respond well to which treatments.